1. 170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study. (December 2022) Authors: Wick, W.; IdBaih, A.; Vieito Villar, M.; Tabatabai, G.; Stradella, A.; Ghiringhelli, F.; Burger, M.; Mildenberger, I.; Herrlinger, U.; Touat, M.; Wen, P.; Wick, A.; Gouttefangeas, C.; Maia, A.; Bonny, C.; Paillarse, J-M.; Fagerberg, J.; Reardon, D.A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 185P Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab. (December 2022) Authors: Wick, W.; Gamelas Magalhaes, J.; Dos Santos Leite, A.M.; IdBaih, A.; Vieito Villar, M.; Tabatabai, G.; Stradella, A.; Ghiringhelli, F.; Burger, M.; Mildenberger, I.; Herrlinger, U.; Touat, M.; Wen, P.; Wick, A.; Toussaint, H.; Gouttefangeas, C.; Bonny, C.; Paillarse, J-M.; Reardon, D.A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗